Last reviewed 2026-04-23 · How we verify

M-VTD-PACE

M-VTD-PACE is a combination chemotherapy and immunotherapy regimen that uses multiple agents to target and kill multiple myeloma cells through different mechanisms.

M-VTD-PACE is a combination chemotherapy and immunotherapy regimen that uses multiple agents to target and kill multiple myeloma cells through different mechanisms. Used for Multiple myeloma (high-risk disease), Relapsed/refractory multiple myeloma.

At a glance

Mechanism of action

M-VTD-PACE combines bortezomib (proteasome inhibitor), thalidomide (immunomodulator), dexamethasone (corticosteroid), cisplatin, doxorubicin, cyclophosphamide, and etoposide. The regimen works by inhibiting proteasome function, modulating immune response, and providing direct cytotoxic chemotherapy. This multi-agent approach is designed to overcome drug resistance and improve outcomes in multiple myeloma patients, particularly those with high-risk disease.

Approved indications

• Multiple myeloma (high-risk disease)
• Relapsed/refractory multiple myeloma

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Neuropathy
• Infection
• Nausea/vomiting
• Mucositis

Key clinical trials

• UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (PHASE3)
• UARK 2003-33, Total Therapy III (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• M-VTD-PACE CI brief — competitive landscape report
• M-VTD-PACE updates RSS · CI watch RSS
• University of Arkansas portfolio CI